Lavomax 125 mg tablets 3

Country

Russia

INN

Tiloron

Dosage

125mg

Composition

Active substance: tilorona dihydrochloride 125 mg.

Excipients: magnesium hydroxycarbonate (magnesium carbonate heavy), povidone K30, calcium stearate.

Shell composition: sucrose, povidone K17, copovidone, magnesium hydroxycarbonate (magnesium carbonate light), titanium dioxide, silicon dioxide colloidal (aerosil A-380), quinoline yellow dye, sunset yellow dye, macrogol 6000, beeswax, liquid paraffin, talc.

Pharmacological properties

Antiviral and immunomodulatory drug. Lavomax ^® stimulates the formation of α-, β-, γ-interferons in the body. In response to the administration of Lavomax, interferon is produced mainly by intestinal epithelial cells, hepatocytes, T-lymphocytes and neutrophils.

After taking the drug inside the maximum interferon production is determined in the sequence of intestine-liver-blood after 4-24 h. Lavomax ^® has an immunomodulatory and antiviral effect. Stimulates bone marrow stem cells, depending on the dose, enhances antibody formation, reduces the degree of immunosuppression, restores the ratio of T-helpers / T-suppressors.

Effective against various viral infections, including influenza viruses, other acute respiratory viral infections, hepatitis and herpes viruses, cytomegaloviruses and neurotropic viruses.

The mechanism of antiviral action is associated with the inhibition of the translation of virus-specific proteins in infected cells, as a result of which the reproduction of viruses is suppressed.

Indications for use

The drug is used in adults as part of complex therapy:

• viral hepatitis A, B and C;
• herpes infection;
• cytomegalovirus infection;
• infectious-allergic and viral encephalomyelitis;
• urogenital and respiratory chlamydia;
• non-gonococcal urethritis;
• pulmonary tuberculosis.

Treatment and prevention of influenza and other ARVI.

Contraindications

• pregnancy;
• lactation (breastfeeding);
• children and adolescents up to 18 years;
• deficiency of sucrase / isomaltase, fructose intolerance, glucose-galactose malabsorption (the drug contains sucrose);
• hypersensitivity to the components of the drug.

Use in pregnancy and lactation

Lavomax ^® contraindicated for use during pregnancy and lactation (breastfeeding).

Use in children

Contraindicated in childhood and adolescence under the age of 18.

Special instructions

Influence on the ability to drive vehicles and control mechanisms

The use of the drug does not affect the ability to drive vehicles and engage in other potentially dangerous activities that require increased concentration of attention and speed of psychomotor reactions.

Drug Interactions

Clinically Significant Interactions of lavomax ^® with antibiotics, standard therapy for viral and bacterial diseases, alcohol has not been detected.

Compatible with antibiotics and standard therapy for viral and bacterial diseases.

Dosage and Administration

The drug is taken orally, after meals.

In the treatment of influenza and other acute respiratory viral infections - in the first two days of the disease - 125 mg each, then - every other day at 125 mg. Course dose - 750 mg (for the course of treatment - 6 tab. 125 mg each).

For the prevention of influenza and other acute respiratory viral infections - 125 mg 1 time per week for 6 weeks. For the course of treatment - 6 tab. 125 mg each.

For the treatment of viral hepatitis A - the first day, 125 mg 2 times, then - 125 mg every other day. The course dose is 1.25 g (for the course of treatment - 10 tab. 125 mg each).

For the treatment of acute hepatitis B - the first and second days of 125 mg, then - 125 mg every other day. The course dose is 2 g (for the course of treatment - 16 tab. 125 mg each), with a protracted course of hepatitis B - 125 mg 2 times / day on the first day, then - 125 mg every other day. The course dose is 2.5 g (for the course of treatment - 20 tab. 125 mg each).

In chronic hepatitis B - the initial phase of treatment (2.5 g) - the first two days of 250 mg, then - 125 mg every other day. Continuation phase (from 1.25 g to 2.5 g) - 125 mg per week. Course dose of Lavomax ^® from 3.75 to 5 g (for the course of treatment - from 30 to 40 tab. 125 mg), the duration of therapy is 3.5-6 months, depending on the results of biochemical, immunological, morphological studies, reflecting the degree of activity of the process.

In acute hepatitis C - the first and second days of 125 mg, then - 125 mg every other day. Course dose - 2.5 g (for the course of treatment - 20 tab. 125 mg each).

In chronic hepatitis C - the initial phase of treatment (2.5 g) - the first two days of 250 mg, then - 125 mg every other day. Continuation phase (2.5 g) - 125 mg per week. Course dose of Lavomax ^® - 5 g (for the course of treatment - 40 tab. 125 mg each). The duration of therapy is 6 months, depending on the results of biochemical, immunological, morphological markers of the activity of the process.

For the treatment of herpetic, cytomegalovirus infection - the first two days at 125 mg, then - every other day at 125 mg. Course dose - 2.5 g (for the course of treatment - 20 tab. 125 mg each).

At urogenital and respiratory chlamydia, non-gonococcal urethritis - the first two days of 125 mg, then - every other day at 125 mg. Course dose - 1.25 g (for the course of treatment - 10 tab. 125 mg each).

As part of the complex therapy of pulmonary tuberculosis - the first two days of 250 mg, then - 125 mg every other day. Course dose - 2.5 g (for the course of treatment - 20 tab. 125 mg each).

As part of the complex therapy of neuroviral infections, the dose is set individually, the course of treatment is 4 weeks.

Side effects

Allergic reactions, dyspeptic phenomena, short-term chills are possible. If any of the side effects listed in the instructions are aggravated, or you notice any other side effects not listed in the instructions, tell your doctor.

Storage conditions

In a dry, dark place at a temperature not exceeding 25 ° C. Keep out of the reach of children.

Shelf life 2 years.